Shilpa Medicare Subsidiary Settles Dispute with Sartorius for Rs 9 Crore
Shilpa Biologicals Pvt. Ltd., a material subsidiary of Shilpa Medicare Limited, has reached an amicable settlement agreement with Sartorius Stedim India Pvt. Ltd. regarding a commercial dispute that was adjudicated in the Commercial Court in Bengaluru.The settlement agreement was executed on June 23, 2026, following negotiations between both parties before the Hon'ble XI Addl. City Civil and Sessions Court in Bengaluru (Commercial O.S. No. 153/2024).
Shilpa Biologicals Pvt. Ltd. committed to paying a settlement amount of Rs 9,00,00,000 to Sartorius Stedim India Pvt. Ltd.
Dispute Details
The dispute involved an alleged claim made by Sartorius, which amounted to Rs 20,13,47,308, along with applicable interest. Both parties subsequently negotiated and signed the settlement agreement to resolve the matter.The details of the court proceeding and the resolution are summarized below:
| Particulars | Details |
|---|---|
| Authority Involved | Hon'ble XI Addl. City Civil and Sessions Court, Commercial Court, Bengaluru |
| Agreement Date | June 23, 2026 |
| Settlement Amount Paid | Rs 9,00,00,000 |
| Original Alleged Claim | Rs 20,13,47,308 plus interest |
The financial impact of this settlement is expected to be limited to the specified settlement amount.
SHILPAMED Stock Price Movement
Shares of Shilpa Medicare Limited today slipped by 2.06%, settling at ₹579.65 in post-market trading. The stock closed amidst significant selling, trading on a volume of 947,852 shares after reaching a low of ₹573.7 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.